KRINGLE PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 661 JPY | +1.69% |
|
+22.86% | -12.10% |
Valuation
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 3,919 | 2,421 | 4,318 |
| Enterprise Value (EV) 1 | 1,782 | -334.7 | 2,182 |
| P/E ratio | -12.5 x | -6.6 x | -5.04 x |
| Yield | - | - | - |
| Capitalization / Revenue | 13,560,121 x | 6,192,521 x | 62,574,916 x |
| EV / Revenue | 6,165,657 x | -856,072 x | 31,618,394 x |
| EV / EBITDA | - | - | - |
| EV / FCF | -3,523,233 x | 1,806,878 x | -4,050,442 x |
| FCF Yield | -0% | 0% | -0% |
| Price to Book | 1.57 x | 0.87 x | 2.13 x |
| Nbr of stocks (in thousands) | 4,321 | 5,381 | 5,411 |
| Reference price 2 | 907.0 | 450.0 | 798.0 |
| Announcement Date | 27/12/21 | 26/12/22 | 25/12/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 467 | 289 | 391 | 69 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -223 | -371 | -172 | -358 | -426 | -889 |
| Operating Margin | - | - | -36.83% | -123.88% | -108.95% | -1,288.41% |
| Earnings before Tax (EBT) 1 | -64 | -302 | -116 | -300 | -330 | -853 |
| Net income 1 | -64 | -302 | -117 | -301 | -331 | -854 |
| Net margin | - | - | -25.05% | -104.15% | -84.65% | -1,237.68% |
| EPS 2 | -61.48 | -290.1 | -105.9 | -72.47 | -68.16 | -158.4 |
| Free Cash Flow | - | - | - | -505.8 | -185.2 | -538.6 |
| FCF margin | - | - | - | -175% | -47.38% | -780.62% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 24/11/20 | 24/11/20 | 24/11/20 | 27/12/21 | 26/12/22 | 25/12/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2020 S1 | 2021 S1 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 117 | 13 | 27 | 85 | 17 | 34 | 17 | 18 | 43 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -169 | -120 | -310 | -73 | -157 | -314 | -306 | -168 | -366 |
| Operating Margin | - | -144.44% | -923.08% | -1,148.15% | -85.88% | -923.53% | -923.53% | -1,800% | -933.33% | -851.16% |
| Earnings before Tax (EBT) 1 | - | -191 | -128 | -318 | 13 | -157 | -314 | -263 | -169 | -365 |
| Net income 1 | - | -192 | -129 | -319 | 13 | -157 | -315 | -263 | -169 | -366 |
| Net margin | - | -164.1% | -992.31% | -1,181.48% | 15.29% | -923.53% | -926.47% | -1,547.06% | -938.89% | -851.16% |
| EPS 2 | - | -48.33 | -29.02 | -70.24 | 5.220 | -29.34 | -58.63 | -48.82 | -29.53 | -60.21 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | - | 14/05/21 | 14/02/22 | 13/05/22 | 12/08/22 | 10/02/23 | 15/05/23 | 14/08/23 | 09/02/24 | 13/05/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 505 | 166 | 2,102 | 2,137 | 2,756 | 2,136 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | -506 | -185 | -539 |
| ROE (net income / shareholders' equity) | - | -82.3% | -9.73% | -12.8% | -12.5% | -35.5% |
| ROA (Net income/ Total Assets) | - | -56.8% | -8.27% | -8.98% | -9.11% | -19.1% |
| Assets 1 | - | 532 | 1,415 | 3,353 | 3,632 | 4,477 |
| Book Value Per Share 2 | 498.0 | 207.0 | 1,691 | 578.0 | 518.0 | 374.0 |
| Cash Flow per Share 2 | 485.0 | 159.0 | 1,624 | 493.0 | 512.0 | 395.0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 24/11/20 | 24/11/20 | 24/11/20 | 27/12/21 | 26/12/22 | 25/12/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.10% | 27.48M | |
| +32.64% | 50.93B | |
| -0.53% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +10.95% | 26.02B | |
| -22.41% | 18.9B | |
| +7.78% | 13.21B | |
| +24.29% | 12.17B | |
| +28.94% | 12.16B |
- Stock Market
- Equities
- 4884 Stock
- Financials Kringle Pharma, Inc.
